2. Search Result
Search Result
Results for "

behaviour

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

1

Biochemical Assay Reagents

4

Peptides

6

Natural
Products

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108677
    L-368,899 hydrochloride
    Maximum Cited Publications
    7 Publications Verification

    		 Oxytocin Receptor Endocrinology
    L-368,899 hydrochloride is a potent, selective, orally bioavailable, non-peptide oxytocin receptor antagonist, with IC50s of 8.9 nM and 26 nM for rat uterus and human uterus oxytocin receptor, respectively. L-368,899 hydrochloride used as a tocolytic agent .
    L-368,899 hydrochloride
  • HY-B0188A
    Mianserin hydrochloride
    1 Publications Verification

    Org GB 94

    		 Histamine Receptor Opioid Receptor ERK p38 MAPK Neurological Disease Metabolic Disease
    Mianserin hydrochloride (Org GB 94) is an orally active H1 receptor antagonist. Mianserin hydrochloride can activate κ-opioid receptor and octopamine receptor. Mianserin hydrochloride increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin hydrochloride modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin hydrochloride can be used for the research of neurological disease, such as depression and epilepsy .
    Mianserin hydrochloride
  • HY-N6967
    Levomenol

    (-)-α-Bisabolol

    		 Environmental Pollutants Apoptosis Neurological Disease Inflammation/Immunology
    Levomenol ((-)-α-Bisabolol), a monocyclic sesquiterpene alcohol, exerts antioxidant, anti-inflammatory, and anti-apoptotic activities. Levomenol also has neuroprotective effects and prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice. Levomenol attenuates nociceptive behaviour and central sensitisation in a rodent model of trigeminal neuropathic pain. Orally active .
    Levomenol
  • HY-A0081
    Fluphenazine dihydrochloride
    3 Publications Verification

    		 Dopamine Receptor SARS-CoV Sodium Channel Neurological Disease Cancer
    Fluphenazine dihydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dihydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine dihydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dihydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dihydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .
    Fluphenazine dihydrochloride
  • HY-B0188
    Mianserin
    1 Publications Verification

    Mianserine

    		 Histamine Receptor Opioid Receptor ERK p38 MAPK Neurological Disease
    Mianserin (Mianserine) is an orally active H1 receptor antagonist. Mianserin can activate κ-opioid receptor and octopamine receptor. Mianserin increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin can be used for the research of neurological disease, such as depression and epilepsy .
    Mianserin
  • HY-119980
    Fluphenazine
    3 Publications Verification

    		 Sodium Channel Dopamine Receptor SARS-CoV Infection Neurological Disease Cancer
    Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .
    Fluphenazine
  • HY-18779
    PF-4840154
    1 Publications Verification

    		 TRP Channel Inflammation/Immunology
    PF-4840154 is a potent, selective agonist of the rat and human TrpA1 channel with EC50s of 97 and 23 nM, respectively. PF-4840154 elicits TrpA1-mediated nocifensive behaviour in mouse .
    PF-4840154
  • HY-139065
    AMPC

    		Apoptosis Cancer
    AMPC is a potent and effective TFF3 inhibitor. AMPC inhibits cell proliferation, survival, oncogenicity, and CSC-like behaviour in TFF3-positive CMS4 CRC cells. AMPC acts as a potential anti-cancer agent alone or in combination with 5-FU, and can be used for cancer research .
    AMPC
  • HY-P1213
    JKC363

    		Melanocortin Receptor Neurological Disease
    JKC363, a selective melanocortin MC4 receptor antagonist, has a 90-fold higher affinity at the MC4 receptor (IC50=0.5 nM) than at the MC3 receptor (44.9 nM). JKC-363 blocks the stimulatory effect of α-MSH on TRH release. Anti-hyperalgesic effect .
    JKC363
  • HY-139126
    (±)-Muscarine chloride

    DL-Muscarin chloride

    		 mAChR Neurological Disease
    (±)-Muscarine chloride is the racemate of Muscarine chloride. Muscarine is a prototype muscarinic acetylcholine receptor agonist .
    (±)-Muscarine chloride
  • HY-119468
    Medifoxamine

    		Dopamine Transporter Neurological Disease
    Medifoxamine is an orally active monoamine reuptake inhibitor and antidepressant. Medifoxamine preferentially inhibits presynaptic dopamine reuptake. Medifoxamine acts as an intraocular pressure-lowering agent to reduce intraocular pressure, and also functions as a miotic agent to decrease pupil diameter. Medifoxamine exhibits characteristic properties of antidepressant compounds, including preventing hypothermia induced by Reserpine (HY-N0480) or Apomorphine (HY-12723), potentiating the toxic effects of Yohimbine (HY-N0127) in mice, and reducing immobility behavior in mice and rats in the "behavioral despair" model. Medifoxamine has no anticholinergic activity. Medifoxamine can be used in research related to depression .
    Medifoxamine
  • HY-137231B
    (S)-UFR2709 hydrochloride

    		nAChR Neurological Disease
    (S)-UFR2709 (hydrochloride) is a competitive nAChR antagonist?and displays higher affinity for α4β2 nAChRs than for α7 nAChRs. (S)-UFR2709 (hydrochloride) decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 (hydrochloride) acts as an anxiolytic agent and can be used for the study of nicotine addiction .
    (S)-UFR2709 hydrochloride
  • HY-138693
    ST4070

    		FAAH Neurological Disease
    ST4070 is a potent, orally active, and selective reversible fatty acid amide hydrolase (FAAH) inhibitor. ST4070 increases endocannabinoid (eCB) brain levels and counteracts neuropathic pain in animal models. ST4070 enhances the endogenous eCB tone in specific brain regions engaged in emotional control, and induces remarkable anxiolytic-like behaviours in rodents. ST4070 can be used for neuropathic pain and anxiety disorders research .
    ST4070
  • HY-119980S
    Fluphenazine-d8

    		Isotope-Labeled Compounds Sodium Channel Dopamine Receptor SARS-CoV Others
    Fluphenazine-d8 is the deuterium labeled Fluphenazine. Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .
    Fluphenazine-d8
  • HY-B0188AR
    Mianserin hydrochloride (Standard)

    Org GB 94 (Standard)

    		 Reference Standards Histamine Receptor Opioid Receptor ERK p38 MAPK Neurological Disease Metabolic Disease
    Mianserin hydrochloride (Org GB 94) (Standard) is the analytical standard of Mianserin hydrochloride. This product is intended for research and analytical applications. Mianserin hydrochloride is an orally active H1 receptor antagonist. Mianserin hydrochloride can activate κ-opioid receptor and octopamine receptor. Mianserin hydrochloride increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin hydrochloride modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin hydrochloride can be used for the research of neurological disease, such as depression and epilepsy .
    Mianserin hydrochloride (Standard)
  • HY-B0188S
    Mianserin-d3

    Mianserine-d3

    		 Histamine Receptor Isotope-Labeled Compounds Opioid Receptor ERK p38 MAPK Neurological Disease
    Mianserin-d3 is the deuterium labeled Mianserin (HY-B0188). Mianserin (Mianserine) is an orally active H1 receptor antagonist. Mianserin can activate κ-opioid receptor and octopamine receptor. Mianserin increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin can be used for the research of neurological disease, such as depression and epilepsy .
    Mianserin-d3
  • HY-167238
    RS-30199

    		5-HT Receptor Neurological Disease
    RS-30199 is an anxiogenic agent. RS-30199 interacts with the 5-HT1A receptor. RS-30199 prolongs intromission latency. RS-30199 fully inhibits the facilitation of sexual behaviour caused by Delequamine (HY-106874) .
    RS-30199
  • HY-B1495
    Quipazine maleate

    		5-HT Receptor Neurological Disease
    Quipazine maleate is a 5-HT agonist that causes behavioural changes such as hyperactivity. Quipazine maleate also shows a weak reversible MAO inhibitory activity .
    Quipazine maleate
  • HY-P11431
    Cyclo(Gly-Pro)

    		IGF-1R Neurological Disease Inflammation/Immunology
    Cyclo(Gly-Pro) is a cyclic dipeptide. Cyclo(Gly-Pro) can be derived from the Nterminus of the IGF-1. Cyclo(Gly-Pro) attenuates nociceptive behaviour and inflammatory response in mice .
    Cyclo(Gly-Pro)
  • HY-W042284
    Tetradecyl acetate

    Myristyl acetate

    		 Sex Pheromone Insecticide Others
    Tetradecyl (Myristyl) acetate is a native sex pheromone component of Yponomeuta rorellus. Tetradecyl acetate elicits orientation behaviour, upwind flight, and landing at the odour source in male Yponomeuta rorellus. Tetradecyl acetate can be used in research on insecticides .
    Tetradecyl acetate
  • HY-136786
    RU-24213 hydrochloride

    		Dopamine Receptor Opioid Receptor Neurological Disease
    RU-24213 hydrochloride is a selective D-2 dopamine receptor agonist. RU-24213 hydrochloride is also a KAPPA-opioid receptor antagonist. RU-24213 hydrochloride induces stereotyped behaviors .
    RU-24213 hydrochloride
  • HY-127120
    Timiperone

    		Dopamine Receptor Neurological Disease
    Timiperone has a strong affinity for cerebral dopamine D2 receptor. Timiperone has antipsychotic activity, and inhibits stereotyped behaviour. Timiperone can be used for research of schizophrenia .
    Timiperone
  • HY-165624
    LY-41

    		Drug Derivative 5-HT Receptor Neurological Disease
    LY-41 is a 2-aminotetralin (HY-W022362) derivative related to 8-OH-DPAT (HY-112061). LY-41 decreases 5-HT synthesis. LY-41 induces 5-HT motor syndrome. (R)-LY-41 and (S)-LY-41 are novel 5-HT1A receptor agonists .
    LY-41
  • HY-P1213A
    JKC363 TFA

    		Melanocortin Receptor Neurological Disease
    JKC363 TFA, a selective melanocortin MC4 receptor antagonist, has a 90-fold higher affinity at the MC4 receptor (IC50=0.5 nM) than at the MC3 receptor (44.9 nM). JKC363 TFA blocks the stimulatory effect of α-MSH on TRH release. Anti-hyperalgesic effect .
    JKC363 TFA
  • HY-106660
    BP 897 hydrochloride

    		Dopamine Receptor Neurological Disease
    BP 897 hydrochloride is a potent and partial dopamine D3 receptor agonist and a weak D2 receptor antagonist. BP 897 hydrochloride displays a high affinity at the dopamine D3 receptor (Ki=0.92 nM) and a 70 times lower affinity at the D2 receptor (Ki=61 nM) .
    BP 897 hydrochloride
  • HY-N6967R
    Levomenol (Standard)

    (-)-α-Bisabolol (Standard)

    		 Reference Standards Apoptosis Neurological Disease Inflammation/Immunology
    Levomenol (Standard) is the analytical standard of Levomenol. This product is intended for research and analytical applications. Levomenol ((-)-α-Bisabolol), a monocyclic sesquiterpene alcohol, exerts antioxidant, anti-inflammatory, and anti-apoptotic activities. Levomenol also has neuroprotective effects and prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice. Levomenol attenuates nociceptive behaviour and central sensitisation in a rodent model of trigeminal neuropathic pain. Orally active .
    Levomenol (Standard)
  • HY-B0188AS
    Mianserin-d3 hydrochloride

    Org GB 94-d3

    		 Isotope-Labeled Compounds Histamine Receptor Opioid Receptor ERK p38 MAPK Neurological Disease Metabolic Disease
    Mianserin-d3 hydrochloride is the deuterium labeled Mianserin. Mianserin (Mianserine) is an orally active H1 receptor antagonist. Mianserin can activate κ-opioid receptor and octopamine receptor. Mianserin increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin can be used for the research of neurological disease, such as depression and epilepsy .
    Mianserin-d3 hydrochloride
  • HY-100679B
    (R)-Pirlindole mesylate

    		Monoamine Oxidase Neurological Disease
    (R)-Pirlindole mesylate is selective and reversible a Monoamine oxidase A (MAO-A) inhibitor with an IC50 of 0.43  μM for MAO-A over MAO-B. (R)-Pirlindole mesylate has an antidepressant activity. (R)-Pirlindole mesylate significantly decreases immobility time of the forced swim test and inhibits Reserpine (HY-N0480)-induced palpebral ptosis in behavioural mice models. (R)-Pirlindole mesylate can be used for depression research .
    (R)-Pirlindole mesylate
  • HY-119980B
    Fluphenazine hydrochloride

    		Dopamine Receptor Sodium Channel SARS-CoV Neurological Disease Cancer
    Fluphenazine hydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine hydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine hydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine hydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine hydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .
    Fluphenazine hydrochloride
  • HY-119980A
    Fluphenazine dimaleate

    		Dopamine Receptor Sodium Channel SARS-CoV Infection Neurological Disease Cancer
    Fluphenazine dimaleate is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dimaleate blocks neuronal voltage-gated sodium channels. Fluphenazine dimaleate acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dimaleate can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dimaleate can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .
    Fluphenazine dimaleate
  • HY-106194
    SLV310

    		Dopamine Receptor Serotonin Transporter Neurological Disease
    SLV310 is an orally active dopamine D2 receptor antagonist (Ki: 5 nM) and serotonin reuptake receptor inhibitor. SLV310 antagonizes Apomorphine (HY-12723) induced climbing behaviour and 5-HTP (HY-N0122) induced serotonin syndrome like behaviour in mice (ED50: 5.6 and 5.9 mg/kg, p.o.). SLV310 is an antipsychotic compound and can be used for schizophrenia research .
    SLV310
  • HY-172381
    Poly(guluronate), low endotoxin

    		Biochemical Assay Reagents Others
    Poly(guluronate), low endotoxin is the portion of the Alginate molecule that is responsible for its gelling behaviour. Poly(guluronate), low endotoxin has ionic cross-linking effects .
    Poly(guluronate), low endotoxin
  • HY-107095
    JNJ19567470

    R317573; CRA5626; TAI041

    		 CRFR Neurological Disease
    JNJ19567470 (R317573) is a selective, non-peptidergic CRF type 1 receptor (CRF1) antagonist. JNJ19567470 blocks NaLac-induced panic-like behaviour and cardiovascular responses. JNJ19567470 decreases regional glucose utilization in the amygdala, and attenuates anxiety responses .
    JNJ19567470
  • HY-114085
    BP 897

    		Dopamine Receptor Neurological Disease
    BP 897 is a potent and partial dopamine D3 receptor agonist and a weak D2 receptor antagonist. BP 897 displays a high affinity at the dopamine D3 receptor (Ki=0.92 nM) and a 70 times lower affinity at the D2 receptor (Ki=61 nM) .
    BP 897
  • HY-137231A
    (S)-UFR2709

    		nAChR Neurological Disease
    (S)-UFR2709 is a competitive nAChR antagonist and displays higher affinity for α4β2 nAChRs than for α7 nAChRs. (S)-UFR2709 decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 acts as an anxiolytic agent and can be used for the study of nicotine addiction .
    (S)-UFR2709
  • HY-10512S
    AR-A014418-d3

    AR 0133418-d3; GSK 3β inhibitor VIII-d3; AR 014418-d3

    		 Isotope-Labeled Compounds GSK-3 Metabolic Disease Cancer
    AR-A014418-d3 is the deuterium labeled AR-A014418. AR-A014418 is a potent, selective, and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM) .
    AR-A014418-d3
  • HY-119980BS
    Fluphenazine-d6 hydrochloride

    		Isotope-Labeled Compounds Dopamine Receptor Sodium Channel SARS-CoV Neurological Disease Cancer
    Fluphenazine-d6 (hydrochloride) is deuterium labeled Fluphenazine (hydrochloride). Fluphenazine hydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine hydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine hydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine hydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine hydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .
    Fluphenazine-d6 hydrochloride
  • HY-A0081R
    Fluphenazine dihydrochloride (Standard)

    		Reference Standards Dopamine Receptor SARS-CoV Sodium Channel Neurological Disease Cancer
    Fluphenazine (dihydrochloride) (Standard) is the analytical standard of Fluphenazine (dihydrochloride). This product is intended for research and analytical applications. Fluphenazine dihydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dihydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine dihydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dihydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dihydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .
    Fluphenazine dihydrochloride (Standard)
  • HY-106660R
    BP 897 hydrochloride (Standard)

    		Reference Standards Dopamine Receptor Neurological Disease
    BP 897 hydrochloride (Standard) is the analytical standard of BP 897 (hydrochloride) (HY-106660). This product is intended for research and analytical applications. BP 897 hydrochloride is a potent and partial dopamine D3 receptor agonist and a weak D2 receptor antagonist. BP 897 hydrochloride displays a high affinity at the dopamine D3 receptor (Ki=0.92 nM) and a 70 times lower affinity at the D2 receptor (Ki=61 nM) .
    BP 897 hydrochloride (Standard)
  • HY-108677R
    L-368,899 hydrochloride (Standard)

    		Reference Standards Oxytocin Receptor Endocrinology
    L-368,899 hydrochloride (Standard) is the analytical standard of L-368,899 hydrochloride (HY-108677). This product is intended for research and analytical applications. L-368,899 hydrochloride is a potent, selective, orally bioavailable, non-peptide oxytocin receptor antagonist, with IC50s of 8.9 nM and 26 nM for rat uterus and human uterus oxytocin receptor, respectively. L-368,899 hydrochloride used as a tocolytic agent .
    L-368,899 hydrochloride (Standard)
  • HY-N12909
    (Z,E)-9,12-Tetradecadienal

    Z9,E12-14:Ald

    		 Others Endocrinology
    (Z,E)-9,12-Tetradecadienal (Z9,E12-14:Ald) is a female pheromone that can induce an electroantennographic response in male antennae, isolated from the sex pheromone extracts of Plodia interpunctella (lepidoptera: pyralidae) .
    (Z,E)-9,12-Tetradecadienal

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: